Home

New Ideas, Inventions and Discoveries

for Modifying the Color of the Human Iris

We combine the latest technology with scientific innovations and discoveries to create new products.

 

The goal is to create state of the art products and medications to treat pathological ocular conditions and also to cosmeticly changing the color of the human eye. To do so, we investigate the latest cutting edge scientific discoveries around the world and incorporate them into new theoretical hypotheses, creating new products.

Contact

Cambyses Biomedical, LLC

Address:
2000 Broadway, Suite 14F
New York, NY 10023
USA
Email:
info@CambysesBiomed.com

Team

Kambiz T. Moazed, MD (Founder and President) has over 30 years of surgical experience in NYC. He received his certification from the American Board of Ophthalmology in 1983. His interest in iris color modification began while he was a research fellow at eye pathology laboratory of Massachusetts Eye and Ear Infirmary at Harvard.

He performed his internship in General Surgery at Stanford University of California. He completed his residency in ophthalmic surgery at Harvard University (ME&EI) in Boston. Dr. Moazed studied the following sub-specialties at Columbia University in NYC: eye plastic and reconstructive surgery, orbital surgery and lacrimal duct surgery. He spent two years in eye pathology fellowships at Stanford and Harvard universities. He was in charge of residency training at Colombia University St. Luke’s-Roosevelt Hospital Centers for 18 years.

He has received a patent for his invention of the laser tear duct probe and tear duct insert, and has filed for a patent on eye color modification.

Roger Cubicciotti, Ph.D. (Corporate Advisor) is an entrepreneur with a passion for market-driven innovation, collaboration and venture development, particularly at the intersection of biotechnology, nanotechnology and clinical medicine. He has spent much of his energy over the past 25 years facilitating commercially directed partnerships among academic, corporate and government stakeholders. Although trained in the physics, chemistry and biology of molecules, cells, tissues and organs, Roger has become increasingly interested in the designed chemistry of teams — helping people work together to achieve common goals. He currently serves on boards of a number of for-profit and nonprofit organizations.

In the past 15 years, Roger has co-founded several companies, including NanoMedica, Molecular Machines, Rational Affinity Devices, Abacus Biocomputing Systems, the Stem Cell Healing Foundation and VentuRealization Foundation. He holds 15 patents on technologies ranging from cardiovascular diagnostics to single-molecule detection, drug delivery, signal processing and photovoltaic devices. Prior to founding NanoMedica, he held research, development and management positions at Stanford University Medical Center, Lawrence Berkeley Laboratory, the Naval Biosciences Laboratory, Corning Medical, Ciba-Corning Diagnostics, Photest Diagnostics and Biotechnology Development Associates. He earned his Ph.D. in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and his bachelor’s degree in Biochemistry from the University of California at Berkeley.

Matthew P. Crugnale (Corporate Advisor) has served as a member of our Board of Directors since our founding in 2009. Mr. Crugnale has had a 50-year career in the electronics industry, and since 1982, he has been the President of Crugnale Associates, a Silicon Valley-based strategic consulting firm. Mr. Crugnale has successfully assisted over 70 start-up and spin-off technology companies. Before starting Crugnale Associates, he was Vice President, International Marketing for Beckman Instruments. Prior to this, Mr. Crugnale spent 20 years as a General Electric executive culminating his GE career as Director, Europe, where he worked directly for Jack Welch. Mr. Crugnale earned a BSEE degree from Case Institute of Technology, and his education includes graduate work at the Massachusetts Institute of Technology s Sloan School of Management and Renesselar Polytechnic Institute. Mr. Crugnale offers our board a deep understanding of the electronics industry gained from over 50 years of experience in the industry and valuable insight into corporate and marketing strategies as the president of his own strategic consulting firm.

 Farhad B Imam, MD, PhD (Scientific Advisor)

Dr. Imam is an Instructor in Medicine at Harvard Medical School and an Attending Physician in Critical Care at Children’s Hospital Boston, where he also trained during residency and fellowship. Prior to his time on the east coast, Dr. Imam earned a B.A in Human Biology. an M.D., and a Ph.D. in Biochemistry at Stanford University via an NIH scholarship awarded in the Medical Scientist Training Program. He is the inventor on an issued medical device patent and founder at Lumos Catheter Systems, Inc., where he is working to develop and market novel catheter localization technology as Chief  Medical Officer and acting CEO.

Hamid R Moazed

After receiving his B.S. in Electrical Engineering from Santa Clara University, Hamid joined a startup company in the Silicon Valley where he wen through the entire cycle of a company’s growth from just 3 engineers to a successful software company with offices around the world. Afterwards he has held many consulting positions in Seattle, San Francisco, and New York, as well as attending San Francisco State University for M.S. in Physics. At present he is working as a senior consultant for a financial technology company. He has played a major role in the startup of Cambyses Biomedical.

David M McConoughey, Esq.  (Patent Attorney) is a registered patent attorney with extensive experience in the private practice of intellectual property law as well as experience as senior level in-house patent counsel.
His practice focuses primarily on the creation and development of the intellectual property assets of entrepreneurs and embryonic and growth stage businesses. Mr. McConoughey is a cofounder and advisor to StormBio, Inc., a development stage biopharmaceutical company, focused on the development of therapeutics for treating Highly Pathogenic Influenza and other acute inflammatory disease by regulating hypercytokinemia (“cytokine storm”).
The scientific and technical subject matter of his work centers on life science, such as medical devices (e.g. orthopedic endoprosthesis and fixation devices) and biotechnology (e.g. cytokine biology and biomolecular diagnostics).